Diagnostics play Genetron raises $75M, looks to NASDAQ for China expansion

Seeking to expand its cancer diagnostics business in China, Genetron proposed a NASDAQ IPO and announced completion of venture financing that together could bring the company up to $175 million.

Beijing-based Genetron Holdings Ltd. raised a total of $75 million Tuesday in the venture financing, comprising $15 million in the second tranche of its series C round and $60 million in a series D round. Vivo Capital backed the series C tranche and co-led the series D round with CICC Healthcare and Alexandria Venture Investments. Giant Plan and ETP BioHealth II Fund participated in the series D...